LOGIN  |  REGISTER
Viking Therapeutics
Recursion

LifeMD to Participate in the Truist Securities Healthcare Disruptors & Digital Health Summit

June 10, 2024 | Last Trade: US$5.66 0.11 -1.91

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that management will be participating in the Truist Securities Healthcare Disruptors & Digital Health Summit taking place June 25-26, 2024 at the Lotte New York Palace. Justin Schreiber, Chief Executive Officer of LifeMD, will be joining a panel discussion titled “Weight Management/Diabetes Care: Tools to Manage Cost vs Benefit.” Management will also be holding one-on-one meetings with investors.

Institutional investors interested in attending the conference and meeting with LifeMD management should contact their Truist Securities representative.

About LifeMD, Inc.

LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women's health, weight management, and hormone therapy. The Company leverages a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.

Investor Contact
Marc Benathen, Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Jessica Friedeman, Chief Marketing Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page